Menu
Currency
GWAS Study

A Genome-Wide Association Study of α-Synuclein Levels in Cerebrospinal Fluid.

Zhong XL, Li JQ, Sun L et al.

29959729 PubMed ID
GWAS Study Type
209 Participants
72 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

ZX
Zhong XL
LJ
Li JQ
SL
Sun L
LY
Li YQ
WH
Wang HF
CX
Cao XP
TC
Tan CC
WL
Wang L
TL
Tan L
YJ
Yu JT
Chapter II

Abstract

Summary of the research findings

α-Synuclein is a 140-amino acid protein produced predominantly by neurons in the brain which plays a role in the regulation of neurotransmitter release, synaptic function, and plasticity, thus making it the focus in understanding the etiology of a group of neurodegenerative diseases. We conducted genome-wide association studies (GWAS) of α-synuclein levels in cerebrospinal fluid (CSF) with 209 non-Hispanic white participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI-1) cohort using a linear regression model to identify novel variants associated with α-synuclein concentration. The minor allele (T) of rs7072338 in the long intergenic non-protein coding RNA 1515 (LINC01515) and the minor allele (T) of rs17794023 in clusterin-associated protein 1 (CLUAP1) were associated with higher CSF α-synuclein levels at genome-wide significance (P = 4.167 × 10-9 and 9.56 × 10-9, respectively). In addition, single nucleotide polymorphisms (SNPs) near amyloid beta precursor protein (APP) (rs1394839) (P = 2.31 × 10-7), Rap guanine nucleotide exchange factor 1 (RAPGEF1) (rs10901091) (P = 8.07 × 10-7), and two intergenic loci on chromosome 2 and 14 (rs11687064 P = 2.50 × 10-7and rs7147386 P = 4.05 × 10-7) were identified as suggestive loci associated with CSF α-synuclein levels. We have identified significantly associated SNPs for CSF α-synuclein. These associations have important implications for a better understanding of α-synuclein regulation and allow researchers to further explore the relationships between these SNPs and α-synuclein-related neurodegenerative disorders.

59 European ancestry individuals with normal cognition, 101 European ancestry individuals with mild cognitive impairment, 49 European ancestry Alzheimer's disease cases

Chapter III

Study Statistics

Key metrics and study information

209
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.